Healthcare -
Biotechnology - NASDAQ - US
$ 2.12
10.4 %
$ 147 M
Market Cap
-0.68
P/E
IKT - COST OF REVENUE
Cost of Revenue IKT - Inhibikase Therapeutics, Inc.
13.6 M
LAST VALUE
9.49%
2 YEAR CAGR
30.15%
5 YEAR CAGR
0.00%
10 YEAR CAGR